Top & Current
Thu, October 3, 2024
[ Thu, Oct 03rd 2024
] - WOPRAI
Tue, October 1, 2024
[ Tue, Oct 01st 2024
] - WOPRAI
Mon, September 23, 2024
[ Mon, Sep 23rd 2024
] - WOPRAI
Mon, September 16, 2024
[ Mon, Sep 16th 2024
] - WOPRAI
Mon, September 9, 2024
[ Mon, Sep 09th 2024
] - WOPRAI
Fri, September 6, 2024
[ Fri, Sep 06th 2024
] - WOPRAI
Tue, August 6, 2024
Mon, July 29, 2024
Thu, June 20, 2024
Wed, June 5, 2024
Thu, May 9, 2024
Wed, April 24, 2024
Wed, April 3, 2024
Mon, January 8, 2024
Fri, September 22, 2023
[ Fri, Sep 22nd 2023
] - WOPRAI
Tue, August 22, 2023
[ Tue, Aug 22nd 2023
] - WOPRAI
[ Tue, Aug 22nd 2023
] - WOPRAI
Tue, August 8, 2023
[ Tue, Aug 08th 2023
] - WOPRAI
Tue, August 1, 2023
[ Tue, Aug 01st 2023
] - WOPRAI
Mon, July 17, 2023
[ Mon, Jul 17th 2023
] - WOPRAI
Fri, July 14, 2023
[ Fri, Jul 14th 2023
] - WOPRAI
Thu, May 18, 2023
[ Thu, May 18th 2023
] - WOPRAI
Tue, March 14, 2023
[ Tue, Mar 14th 2023
] - WOPRAI
Wed, November 2, 2022
[ Wed, Nov 02nd 2022
] - WOPRAI
Tue, August 16, 2022
[ Tue, Aug 16th 2022
] - WOPRAI
Pete Stavropoulos Reiterated (VERA) at Buy and Held Target at $107 on, Oct 3rd, 2024
Pete Stavropoulos of Cantor Fitzgerald, Reiterated "Vera Therapeutics, Inc." (VERA) at Buy and Held Target at $107 on, Oct 3rd, 2024.
Pete has made no other calls on VERA in the last 4 months.
There is 1 other peer that has a rating on VERA. Out of the 1 peers that are also analyzing VERA, 0 agree with Pete's Rating of Hold.
This is the rating of the analyst that currently disagrees with Pete
- Anupam Rama of "JP Morgan" Maintained at Buy with Increased Target to $72 on, Tuesday, September 3rd, 2024